Abstracts by key term: Germany
Adipositas und ihre Folgeerkrankungen zählen weltweit zu den bedeutendsten Herausforderungen für die öffentliche Gesundheit. Mit der steigenden Verbreitung von Adipositas nehmen auch kardiometabolische Erkrankungen (z. B. Typ-2-Diabetes mellitus, arterielle Hypertonie, koronare Herzkrankheit und Herzinsuffizienz), bestimmte Tumorerkrankungen und Muskel-Skelett-Erkrankungen zu. Bei Erwachsenen in Deutschland zählt ein höherer Body-Mass-Index (BMI) zu den größten Risikofaktoren im Hinblick auf die […]
05.10.2026
This study examined the costs of a combination therapy of exenatide (EXE) and an oral antidiabetic drug (OAD) versus basal-supported oral therapy (BOT) with insulin glargine (GLA) in antihyperglycemic treatment in type 2 diabetics in Germany based on healthcare data . A historical cohort study was conducted using the representative IMS® Disease Analyzer database. Type 2 diabetics who started BOT with GLA or combination therapy with EXE and OAD between 1/2007 and 12/2008 were included.
23.09.2012
Diabetes mellitus has become a widespread disease in Germany. There are at least 7 million people with diagnosed diabetes mellitus in Germany and, taking into account the undiagnosed cases and the increasing prevalence of the disease worldwide, especially among younger people, the German health system will face major challenges, including economic ones. Under certain conditions, self-monitoring of blood sugar can be a very useful and cost-effective therapeutic element in the treatment of the disease. Although this benefit in insulin-dependent diabetics is largely undisputed, there is still no consensus in Germany about the benefit in non-insulin-dependent type 2 diabetics. However, what is often overlooked in the benefit assessment is that self-measurement of blood glucose is a diagnostic procedure which – unlike medicines – cannot have an intrinsic effect. Applying drug evaluation methods to a diagnostic procedure can subsequently lead to misleading results. If blood glucose measurement is used correctly by patients and appropriate assessment methods are used, self-assessment of blood glucose in type 2 patients even proves to be cost-saving for health insurance companies.